Journal
JOURNAL OF NUCLEAR MEDICINE
Volume 61, Issue 2, Pages 172-176Publisher
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.119.228858
Keywords
estrogen receptor; progesterone receptor; PET/CT; breast cancer
Funding
- Clinical and Translational Science Award program through the NIH National Center for Advancing Translational Sciences [1UL1TR002373]
- University of Wisconsin Institute of Clinical and Translational Research (KL2 scholar award) [1KL2TR002374]
Ask authors/readers for more resources
Estrogen receptor (ER) and progesterone receptor (PR) are important prognostic and predictive biomarkers in breast cancer. PET using ER- and PR-specific radioligands enables a whole-body, noninvasive assessment of receptor expression. Recent investigations of ER imaging with F-18-fluoroestradiol have focused on diagnosing ER-positive metastatic disease, optimizing ER-targeted drug dosage, and predicting endocrine therapy benefit. Studies of PR imaging with F-18-fluorofuranyl norprogesterone have investigated how imaging changes in PR expression as a downstream target of ER activation may reflect an early response to ER-targeted therapy. This focused review highlights recent achievements in preclinical and clinical imaging of ER and PR in breast cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
